Athena Athena

X
[{"orgOrder":0,"company":"AiPharma","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.A.E","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"}]

Find Clinical Drug Pipeline Developments & Deals by AiPharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The partnership between Appili and AiPharma will include the formation of a joint scientific committee to further coordinate clinical and regulatory activities for global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral.

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

            Highest Development Status: Phase IV Product Type: Small molecule

            Partner/Sponsor/Collaborator: Appili Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY